Stock CGTX COGNITION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cognition Therapeutics, Inc.

Equities

CGTX

US19243B1026

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
1.91 USD -1.04% Intraday chart for Cognition Therapeutics, Inc. -4.50% +3.24%
Apr. 29 Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies CI
Apr. 12 Transcript : Cognition Therapeutics, Inc. - Special Call

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
AQ
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's disease
AQ
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
AQ
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
GL
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
AQ
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
GL
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
GL
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
AQ
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
GL
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
GL
Cognition Therapeutics : Results of Operations and Financial Condition - Form 8-K
PU
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
GL
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
AQ
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
GL
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
AQ
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
AQ
Cognition Therapeutics CEO Issues Letter to Shareholders
GL
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
AQ
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
AQ
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGTX Stock
  4. News Cognition Therapeutics, Inc.
  5. Press Releases